Acute kidney injury (AKI) is a prevalent and serious clinical challenge with limited specific treatments. Phyllanthus urinaria L (PU), a well-regarded herbal medicine, possesses noted anti-inflammatory, antiviral, and antitumor properties. Yet, research into its renal protective effects, particularly for cisplatin-induced AKI, is markedly limited. Our study explores the therapeutic potential of PU against AKI triggered by cisplatin administration. Utilizing an AKI model induced by a substantial dose of cisplatin, we assessed renal function through histological examination (hematoxylin and eosin staining) and biochemical markers, including blood urea nitrogen (BUN) and serum creatinine (Scr). Our results demonstrated that PU may mitigate cisplatin's structural damage to renal tissue. Post-treatment with PU, a significant reduction in pro-inflammatory cytokines interleukin-1β (IL-1β), IL-6, and tumor necrosis factor-α (TNF-α) was observed through quantitative polymerase chain reaction (PCR) analysis. Additionally, the expressions of apoptotic and anti-apoptotic proteins B cell leukemia/lymphoma two (Bcl-2), Bcl2-Associated X protein (Bax), and cleaved-caspase3 evaluated via Western blot and immunofluorescence indicated that PU could inhibit apoptosis in response to cisplatin injury. Oxidative stress markers, such as malondialdehyde (MDA) and superoxide dismutase (SOD), showed decreased MDA levels and elevated SOD activity following PU treatment, suggesting a reduction in oxidative damage. Furthermore, cisplatin-induced downregulation of NRF2 and NQO1 was countered by PU, highlighting its restorative effect on antioxidant pathways as confirmed by Western blot and immunofluorescence. Collectively, our findings endorse PU's protective capability against cisplatin-induced AKI, endorsing its therapeutic potential to counteract cisplatin's nephrotoxicity.
| [1] |
E. A. J. Hoste, J. A. Kellum, N. M. Selby, et al., “Global Epidemiology and Outcomes of Acute Kidney Injury,” Nature Reviews Nephrology14, no. 10 (2018): 607-625.
|
| [2] |
C. Ronco, R. Bellomo, and J. A. Kellum, “Acute Kidney Injury,” Lancet.394, no. 10212 (2019): 1949-1964.
|
| [3] |
R. Wiersema, R. J. Eck, M. Haapio, et al., “Burden of Acute Kidney Injury and 90-day Mortality in Critically Ill Patients,” BMC Nephrology21, no. 1 (2019): 1.
|
| [4] |
X. Xu, S. Nie, Z. Liu, et al., “Epidemiology and Clinical Correlates of AKI in Chinese Hospitalized Adults,” Clinical Journal of the American Society of Nephrology10, no. 9 (2015): 1510-1518.
|
| [5] |
R. L. Mehta, M. T. Pascual, S. Soroko, et al., “Spectrum of Acute Renal Failure in the Intensive Care Unit: The PICARD Experience,” Kidney International66, no. 4 (2004): 1613-1621.
|
| [6] |
E. A. Hoste, S. M. Bagshaw, R. Bellomo, et al., “Epidemiology of Acute Kidney Injury in Critically Ill Patients: The Multinational AKI-EPI Study,” Intensive Care Medicine41, no. 8 (2015): 1411-1423.
|
| [7] |
C. Tang, M. J. Livingston, R. Safirstein, and Z. Dong, “Cisplatin Nephrotoxicity: New Insights and Therapeutic Implications,” Nature Reviews Nephrology19, no. 1 (2023): 53-72.
|
| [8] |
S. Latcha, E. A. Jaimes, S. Patil, I. G. Glezerman, S. Mehta, and C. D. Flombaum, “Long-Term Renal Outcomes After Cisplatin Treatment,” Clinical Journal of the American Society of Nephrology11, no. 7 (2016): 1173-1179.
|
| [9] |
S. J. Holditch, C. N. Brown, A. M. Lombardi, K. N. Nguyen, and C. L. Edelstein, “Recent Advances in Models, Mechanisms, Biomarkers, and Interventions in Cisplatin-Induced Acute Kidney Injury,” International Journal of Molecular Sciences20, no. 12 (2019): 3011.
|
| [10] |
R. Wald, W. Beaubien-Souligny, R. Chanchlani, et al., “Delivering Optimal Renal Replacement Therapy to Critically Ill Patients With Acute Kidney Injury,” Intensive Care Medicine48, no. 10 (2022): 1368-1381.
|
| [11] |
C. Y. Fang, D. Y. Lou, L. Q. Zhou, et al., “Natural Products: Potential Treatments for Cisplatin-Induced Nephrotoxicity,” Acta Pharmacologica Sinica42, no. 12 (2021): 1951-1969.
|
| [12] |
H. Fang, G. Dai, B. Liao, P. Zhou, and Y. Liu, “Application of Chloroplast Genome in the Identification of Phyllanthus Urinaria and its Common Adulterants,” Frontiers in Plant Science13 (2023): 1099856.
|
| [13] |
M. Geethangili and S. T. Ding, “A Review of the Phytochemistry and Pharmacology of Phyllanthus Urinaria L,” Frontiers in Pharmacology9 (2018): 1109.
|
| [14] |
F. C. Liu, I. H. Chaudry, and H. P. Yu, “Hepatoprotective Effects of Corilagin Following Hemorrhagic Shock Are through Akt-dependent Pathway,” Shock47, no. 3 (2017): 346-351.
|
| [15] |
L. Chularojmontri, Y. Ihara, E. Muroi, S. Goto, T. Kondo, and S. K. Wattanapitayakul, “Cytoprotective Role of Phyllanthus Urinaria L. And Glutathione-S Transferase Pi in Doxorubicin-Induced Toxicity in H9c2 Cells,” Medical Journal of the Medical Association of Thailand92, no. Suppl 3 (2009): S43-S51.
|
| [16] |
B. T. D. Trinh, D. Staerk, and A. K. Jäger, “Screening for Potential α-glucosidase and α-amylase Inhibitory Constituents From Selected Vietnamese Plants Used to Treat Type 2 Diabetes,” Journal of Ethnopharmacology186 (2016): 189-195.
|
| [17] |
T. X. Zhao, J. K. Wang, L. J. Shen, et al., “Increased m6A RNA Modification Is Related to the Inhibition of the Nrf2-Mediated Antioxidant Response in Di-(2-ethylhexyl) Phthalate-Induced Prepubertal Testicular Injury,” Environment and Pollution259 (2020): 113911.
|
| [18] |
T. Zhao, X. Tang, D. Li, et al., “Prenatal Exposure to Environmentally Relevant Levels of PBDE-99 Leads to Testicular Dysgenesis With Steroidogenesis Disorders,” Journal of Hazardous Materials424, no. Pt B (2022): 127547.
|
| [19] |
Y. Qu, F. An, Y. Luo, et al., “A Nephron Model for Study of Drug-Induced Acute Kidney Injury and Assessment of Drug-Induced Nephrotoxicity,” Biomaterials155 (2018): 41-53.
|
| [20] |
M. A. Perazella, “Pharmacology behind Common Drug Nephrotoxicities,” Clinical Journal of the American Society of Nephrology13, no. 12 (2018): 1897-1908.
|
| [21] |
M. A. Perazella and M. H. Rosner, “Drug-Induced Acute Kidney Injury,” Clinical Journal of the American Society of Nephrology17, no. 8 (2022): 1220-1233.
|
| [22] |
N. Giribabu, K. Karim, E. K. Kilari, and N. Salleh, “Phyllanthus Niruri Leaves Aqueous Extract Improves Kidney Functions, Ameliorates Kidney Oxidative Stress, Inflammation, Fibrosis and Apoptosis and Enhances Kidney Cell Proliferation in Adult Male Rats With Diabetes Mellitus,” Journal of Ethnopharmacology205 (2017): 123-137.
|
| [23] |
S. Wang, S. Huang, X. Liu, Y. He, and Y. Liu, “Paricalcitol Ameliorates Acute Kidney Injury in Mice by Suppressing Oxidative Stress and Inflammation via Nrf2/HO-1 Signaling,” International Journal of Molecular Sciences24, no. 2 (2023): 969.
|
| [24] |
H. Wang, W. Xia, G. Long, et al., “Isoquercitrin Ameliorates Cisplatin-Induced Nephrotoxicity via the Inhibition of Apoptosis, Inflammation, and Oxidative Stress,” Frontiers in Pharmacology11 (2020): 599416.
|
| [25] |
A. Havasi and S. C. Borkan, “Apoptosis and Acute Kidney Injury,” Kidney International80, no. 1 (2011): 29-40.
|
| [26] |
C. A. Davis, H. S. Nick, and A. Agarwal, “Manganese Superoxide Dismutase Attenuates Cisplatin-Induced Renal Injury: Importance of Superoxide,” Journal of the American Society of Nephrology12, no. 12 (2001): 2683-2690.
|
| [27] |
H. Rabb, M. D. Griffin, D. B. McKay, et al., “Inflammation in AKI: Current Understanding, Key Questions, and Knowledge Gaps,” Journal of the American Society of Nephrology27, no. 2 (2016): 371-379.
|
| [28] |
N. Pabla and Z. Dong, “Cisplatin Nephrotoxicity: Mechanisms and Renoprotective Strategies,” Kidney International73, no. 9 (2008): 994-1007.
|
| [29] |
X. L. Zheng, J. J. Yang, Y. Y. Wang, et al., “RIP1 Promotes Proliferation through G2/M Checkpoint Progression and Mediates Cisplatin-Induced Apoptosis and Necroptosis in Human Ovarian Cancer Cells,” Acta Pharmacologica Sinica41, no. 9 (2020): 1223-1233.
|
| [30] |
S. K. Jo, W. Y. Cho, S. A. Sung, H. K. Kim, and N. H. Won, “MEK Inhibitor, U0126, Attenuates Cisplatin-Induced Renal Injury by Decreasing Inflammation and Apoptosis,” Kidney International67, no. 2 (2005): 458-466.
|
| [31] |
R. H. Lee, J. M. Song, M. Y. Park, S. K. Kang, Y. K. Kim, and J. S. Jung, “Cisplatin-induced Apoptosis by Translocation of Endogenous Bax in Mouse Collecting Duct Cells,” Biochemical Pharmacology62, no. 8 (2001): 1013-1023.
|
| [32] |
M. Jiang, X. Yi, S. Hsu, C. Y. Wang, and Z. Dong, “Role of P53 in Cisplatin-Induced Tubular Cell Apoptosis: Dependence on P53 Transcriptional Activity,” American Journal of Physiology - Renal Physiology287, no. 6 (2004): F1140-F1147.
|
| [33] |
N. Ma, W. Wei, X. Fan, and X. Ci, “Farrerol Attenuates Cisplatin-Induced Nephrotoxicity by Inhibiting the Reactive Oxygen Species-Mediated Oxidation, Inflammation, and Apoptotic Signaling Pathways,” Frontiers in Physiology10 (2019): 1419.
|
| [34] |
S. Saha, B. Buttari, E. Panieri, E. Profumo, and L. Saso, “An Overview of Nrf2 Signaling Pathway and its Role in Inflammation,” Molecules25, no. 22 (2020): 5474.
|
| [35] |
M. C. Lu, J. Zhao, Y. T. Liu, et al., “CPUY192018, a Potent Inhibitor of the Keap1-Nrf2 Protein-Protein Interaction, Alleviates Renal Inflammation in Mice by Restricting Oxidative Stress and NF-Κb Activation,” Redox Biology26 (2019): 101266.
|
| [36] |
M. Liu, D. N. Grigoryev, M. T. Crow, et al., “Transcription Factor Nrf2 Is Protective During Ischemic and Nephrotoxic Acute Kidney Injury in Mice,” Kidney International76, no. 3 (2009): 277-285.
|
| [37] |
A. Gaikwad, D. J. Long 2nd, J. L. Stringer, and A. K. Jaiswal, “In Vivo Role of NAD(P)H:quinone Oxidoreductase 1 (NQO1) in the Regulation of Intracellular Redox State and Accumulation of Abdominal Adipose Tissue,” Journal of Biological Chemistry276, no. 25 (2001): 22559-22564.
|
| [38] |
G. S. Oh, H. J. Kim, J. H. Choi, et al., “Pharmacological Activation of NQO1 Increases NAD+ Levels and Attenuates Cisplatin-Mediated Acute Kidney Injury in Mice,” Kidney International85, no. 3 (2014): 547-560.
|
| [39] |
X. Qin, K. Meghana, N. L. Sowjanya, et al., “Embelin Attenuates Cisplatin-Induced Nephrotoxicity: Involving Inhibition of Oxidative Stress and Inflammation in Addition With Activation of Nrf-2/Ho-1 Pathway,” BioFactors45, no. 3 (2019): 471-478.
|
| [40] |
S. Ruiz, P. E. Pergola, R. A. Zager, and N. D. Vaziri, “Targeting the Transcription Factor Nrf2 to Ameliorate Oxidative Stress and Inflammation in Chronic Kidney Disease,” Kidney International83, no. 6 (2013): 1029-1041.
|
| [41] |
W. L. Lau, S. M. Liu, S. Pahlevan, et al., “Role of Nrf2 Dysfunction in Uremia-Associated Intestinal Inflammation and Epithelial Barrier Disruption,” Digestive Diseases and Sciences60, no. 5 (2015): 1215-1222.
|
| [42] |
M. Nezu, T. Souma, L. Yu, et al., “Transcription Factor Nrf2 Hyperactivation in Early-phase Renal Ischemia-Reperfusion Injury Prevents Tubular Damage Progression,” Kidney International91, no. 2 (2017): 387-401.
|
RIGHTS & PERMISSIONS
2025 The Author(s). Pediatric Discovery published by John Wiley & Sons Australia, Ltd on behalf of Children's Hospital of Chongqing Medical University.
PDF
